
Carmine Gazzaruso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2382073/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comment on Khunti et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care 2021;44:2645–2655. Diabetes Care, 2022, 45, e45-e45.	4.3	0
2	Bone microarchitecture abnormalities in type 1 diabetes and in latent autoimmune diabetes in adults. A potential role for C-peptide. Endocrine, 2021, 73, 496-497.	1.1	0
3	Lupus anticoagulant and mortality in patients hospitalized for COVID-19. Journal of Thrombosis and Thrombolysis, 2021, 52, 85-91.	1.0	22
4	Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study. Endocrine, 2021, 71, 59-68.	1.1	34
5	Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin. Clinical Microbiology and Infection, 2021, 27, 637-638.	2.8	9
6	The Effects of COVID-19 on the Eating Habits of Children and Adolescents in Italy: A Pilot Survey Study. Nutrients, 2021, 13, 2641.	1.7	61
7	Bending Resistance at Hip and Fractures Risk in Postmenopausal Women Independent of Bone Mineral Density. Journal of Clinical Densitometry, 2021, , .	0.5	0
8	Association between clitoral tissue perfusion and female sexual dysfunction in healthy women of reproductive age: a pilot study. International Journal of Impotence Research, 2020, 32, 221-225.	1.0	7
9	Association between antithrombin and mortality in patients with COVID-19. A possible link with obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1914-1919.	1.1	46
10	High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clinical Rheumatology, 2020, 39, 2095-2097.	1.0	80
11	Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19. Clinical Rheumatology, 2020, 39, 2475-2477.	1.0	18
12	Effects of C-Peptide Replacement Therapy on Bone Microarchitecture Parameters in Streptozotocin-Diabetic Rats. Calcified Tissue International, 2020, 107, 266-280.	1.5	7
13	Effects of a Portfolio-Mediterranean Diet and a Mediterranean Diet with or without a Sterol-Enriched Yogurt in Individuals with Hypercholesterolemia. Endocrinology and Metabolism, 2020, 35, 298-307.	1.3	5
14	The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Current Opinion in Pharmacology, 2019, 49, 1-5.	1.7	188
15	Transmucosal oxygen tension of the clitoris: a new parameter for future investigations of the sexual, metabolic, and cardiovascular health of women. Endocrine, 2019, 63, 177-181.	1.1	2
16	Cardiovascular characteristics of chronic fatigue syndrome. Biomedical Reports, 2018, 8, 26-30.	0.9	10
17	Microbiota and metabolic diseases. Endocrine, 2018, 61, 357-371.	1.1	280
18	Role of structured individual patient education in the prevention of vascular complications in newly diagnosed type 2 diabetes: the INdividual Therapeutic Education in Newly Diagnosed type 2 diabetes (INTEND) randomized controlled trial. Endocrine, 2018, 60, 46-49.	1.1	14

#	Article	IF	CITATIONS
19	Relationship between high sodium and low PUFA intake and carotid atherosclerosis in elderly women. Experimental Gerontology, 2018, 108, 256-261.	1.2	14
20	Lipid Oxidation Assessed by Indirect Calorimetry Predicts Metabolic Syndrome and Type 2 Diabetes. Frontiers in Endocrinology, 2018, 9, 806.	1.5	18
21	Anti-diabetic agents and heart health: how to use new diabetes medications in a global strategy for the prevention of cardiovascular complications in type 2 diabetes. Annals of Translational Medicine, 2018, 6, 195-195.	0.7	5
22	Association between low C-peptide and fragility fractures in postmenopausal women without diabetes. Journal of Endocrinological Investigation, 2017, 40, 1091-1098.	1.8	7
23	An update on the potential role of C-peptide in diabetes and osteoporosis. Endocrine, 2017, 58, 408-412.	1.1	16
24	Proinsulin C-peptide modulates the expression of ERK1/2, type I collagen and RANKL in human osteoblast-like cells (Saos-2). Molecular and Cellular Endocrinology, 2017, 442, 134-141.	1.6	12
25	Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study. Immunity and Ageing, 2017, 14, 13.	1.8	13
26	Integrated cardiovascular/respiratory control in type 1 diabetes evidences functional imbalance: Possible role of hypoxia. International Journal of Cardiology, 2017, 244, 254-259.	0.8	11
27	Meet Our Section Editor. Current Diabetes Reviews, 2016, 13, 1-1.	0.6	Ο
28	Individuals with Metabolically Healthy Overweight/Obesity Have Higher Fat Utilization than Metabolically Unhealthy Individuals. Nutrients, 2016, 8, 2.	1.7	59
29	Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications?. Endocrine, 2016, 53, 347-349.	1.1	17
30	The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine, 2016, 53, 18-27.	1.1	106
31	Erectile dysfunction as a predictor of asymptomatic coronary artery disease in elderly men with type 2 diabetes. Journal of Geriatric Cardiology, 2016, 13, 552-6.	0.2	5
32	Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes. Osteoporosis International, 2015, 26, 1639-1646.	1.3	22
33	Insulin and GH–IGF-I axis: endocrine pacer or endocrine disruptor?. Acta Diabetologica, 2015, 52, 433-443.	1.2	21
34	Genetic Risk Factors for Diabetic Neuropathy. , 2014, , 63-68.		0
35	Nutrients Utilization in Obese Individuals with and without Hypertriglyceridemia. Nutrients, 2014, 6, 790-798.	1.7	7
36	The link between nutritional parameters and bone mineral density in women: results of a screening programme for osteoporosis. Journal of Translational Medicine, 2014, 12, 46.	1.8	9

#	Article	IF	CITATIONS
37	Cardiovascular Risk in Adult Patients With Growth Hormone (GH) Deficiency and Following Substitution With GH—An Update. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 18-29.	1.8	126
38	Fat utilization and arterial hypertension in overweight/obese subjects. Journal of Translational Medicine, 2013, 11, 159.	1.8	8
39	Metabolic fuel utilization and subclinical atherosclerosis in overweight/obese subjects. Endocrine, 2013, 44, 380-385.	1.1	11
40	Percutaneous transluminal angioplasty for critical limb ischemia in very elderly diabetic patients. Aging Clinical and Experimental Research, 2013, 25, 225-228.	1.4	5
41	Concomitant carotid plaque development and brachial artery diameter enlargement: A retrospective, recall-based study in postmenopausal women. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 765-770.	1.1	2
42	Primary Headache and Silent Myocardial Ischemia in Patients with Coronary Artery Disease. Cardiology, 2013, 125, 133-138.	0.6	2
43	Osteoporosis in chronic inflammatory disease: the role of malnutrition. Endocrine, 2013, 43, 59-64.	1.1	62
44	Transcutaneous Oxygen Tension as a Potential Predictor of Cardiovascular Events in Type 2 Diabetes. Diabetes Care, 2013, 36, 1720-1725.	4.3	39
45	Effect of Different Diabetes Mellitus Treatments on Functional Decline and Death in Elderly Adults with Diabetes Mellitus. Journal of the American Geriatrics Society, 2013, 61, 666-667.	1.3	6
46	Soluble RAGE Plasma Levels in Patients with Coronary Artery Disease and Peripheral Artery Disease. Scientific World Journal, The, 2013, 2013, 1-7.	0.8	29
47	Type 2 Diabetes Mellitus Is Associated With Faster Degeneration of Bioprosthetic Valve. Circulation, 2012, 125, 604-614.	1.6	60
48	Carotid and brachial arterial enlargement in postmenopausal women with hypertension. Menopause, 2012, 19, 145-149.	0.8	12
49	Brachial artery diameter measurement: A tool to simplify non-invasive vascular assessment. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 8-13.	1.1	6
50	Androgens for postmenopausal women's health?. Endocrine, 2012, 42, 514-520.	1.1	26
51	Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients. Internal and Emergency Medicine, 2012, 7, 257-266.	1.0	29
52	An increased risk for fractures: another cause of frailty in HIV-infected subjects. Endocrine, 2012, 41, 347-349.	1.1	6
53	Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine, 2012, 41, 89-95.	1.1	41
54	Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. Journal of Endocrinological Investigation, 2011, 34, 60-64.	1.8	16

#	Article	IF	CITATIONS
55	Diabetes in Cushing syndrome: basic and clinical aspects. Trends in Endocrinology and Metabolism, 2011, 22, 499-506.	3.1	164
56	Large brachial artery diameter and diabetes in post-menopausal women. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 830-834.	1.1	3
57	Erectile Dysfunction and Coronary Artery Disease in Patients with Diabetes. Current Diabetes Reviews, 2011, 7, 143-147.	0.6	32
58	Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine, 2011, 40, 102-108.	1.1	53
59	Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine, 2011, 40, 273-279.	1.1	41
60	Artery remodeling and abdominal adiposity in nonobese postmenopausal women. European Journal of Clinical Nutrition, 2010, 64, 1022-1024.	1.3	13
61	Large Brachial Artery Diameter and Metabolic Syndrome in postmenopausal women. Atherosclerosis, 2010, 210, 458-460.	0.4	9
62	Carotid distension and distensibility impairment in individuals affected by familial combined hyperlipidemia. Atherosclerosis, 2010, 212, 177-180.	0.4	5
63	Large extracoronary artery diameter in obese postmenopausal women. Menopause, 2010, 17, 611-614.	0.8	4
64	TREATMENT WITH METFORMIN IS PROTECTIVE AGAINST LIMITATIONS IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER SUBJECTS WITH TYPE 2 DIABETES MELLITUS. Journal of the American Geriatrics Society, 2009, 57, 562-564.	1.3	7
65	Nutritional Supplements with Oral Amino Acid Mixtures Increases Whole-Body Lean Mass and Insulin Sensitivity in Elderly Subjects with Sarcopenia. American Journal of Cardiology, 2008, 101, S69-S77.	0.7	201
66	Improvement of Blood Glucose Control and Insulin Sensitivity During a Long-Term (60 Weeks) Randomized Study with Amino Acid Dietary Supplements in Elderly Subjects with Type 2 Diabetes Mellitus. American Journal of Cardiology, 2008, 101, S82-S88.	0.7	72
67	Erectile Dysfunction as a Predictor of Cardiovascular Events and Death in Diabetic Patients With Angiographically Proven Asymptomatic Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 51, 2040-2044.	1.2	251
68	Large brachial and common carotid artery diameter in postmenopausal women with carotid atherosclerosis. Atherosclerosis, 2008, 196, 443-448.	0.4	21
69	Biochemical Evaluation of Patients with Active Acromegaly and Type 2 Diabetes Mellitus: Efficacy and Safety of the Galanin Test. Neuroendocrinology, 2008, 88, 299-304.	1.2	12
70	Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes. Age and Ageing, 2008, 37, 222-225.	0.7	30
71	Endogenous testosterone and endothelial function in postmenopausal women. Coronary Artery Disease, 2007, 18, 9-13.	0.3	69
72	Role of endogenous androgens on carotid atherosclerosis in non-obese postmenopausal women. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 705-711.	1.1	20

#	Article	IF	CITATIONS
73	Carotid atherosclerosis associated to metabolic syndrome but not BMI in healthy menopausal women. Diabetes Research and Clinical Practice, 2007, 76, 378-382.	1.1	24
74	Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. Internal and Emergency Medicine, 2007, 2, 19-23.	1.0	57
75	We-P11:266 Erectile dysfunction as predictor of major adverse cardiac events in diabetic patients with silent coronary artery disease. Atherosclerosis Supplements, 2006, 7, 404.	1.2	0
76	Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease. Neuroscience Letters, 2006, 391, 147-149.	1.0	152
77	Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients. International Journal of Cardiology, 2006, 108, 354-358.	0.8	26
78	The M2DM Project. Methods of Information in Medicine, 2006, 45, 79-84.	0.7	36
79	Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. International Journal of Impotence Research, 2006, 18, 311-315.	1.0	31
80	Association of the Metabolic Syndrome and Insulin Resistance With Silent Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2006, 97, 236-239.	0.7	38
81	Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. Expert Review of Cardiovascular Therapy, 2006, 4, 173-180.	0.6	16
82	The M2DM Projectthe experience of two Italian clinical sites with clinical evaluation of a multi-access service for the management of diabetes mellitus patients. Methods of Information in Medicine, 2006, 45, 79-84.	0.7	17
83	Defect of a subpopulation of natural killer immune cells in Graves' disease and Hashimoto's thyroiditis: normalizing effect of dehydroepiandrosterone sulfate. European Journal of Endocrinology, 2005, 152, 703-712.	1.9	26
84	Decreased Release of the Angiogenic Peptide Vascular Endothelial Growth Factor in Alzheimer's Disease: Recovering Effect with Insulin and DHEA Sulfate. Dementia and Geriatric Cognitive Disorders, 2005, 19, 1-10.	0.7	36
85	Relationship Between Erectile Dysfunction and Silent Myocardial Ischemia in Apparently Uncomplicated Type 2 Diabetic Patients. Circulation, 2004, 110, 22-26.	1.6	309
86	Management of Patients with Diabetes Through Information Technology: Tools for Monitoring and Control of the Patients' Metabolic Behavior. Diabetes Technology and Therapeutics, 2004, 6, 567-578.	2.4	40
87	Massive hepatic infarction complicating ultrasound-guided percutaneous radiofrequency thermal ablation. Liver International, 2004, 24, 704-705.	1.9	20
88	Metabolic effects of orally administered amino acid mixture in elderly subjects with poorly controlled type 2 diabetes mellitus. American Journal of Cardiology, 2004, 93, 23-29.	0.7	33
89	Design, Methods, and Evaluation Directions of a Multi-Access Service for the Management of Diabetes Mellitus Patients. Diabetes Technology and Therapeutics, 2003, 5, 621-629.	2.4	58
90	Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients. Journal of Diabetes and Its Complications, 2003, 17, 135-140.	1.2	12

#	Article	IF	CITATIONS
91	Restenosis after intracoronary stent placement: can apolipoprotein(a) polymorphism play a role?. International Journal of Cardiology, 2003, 87, 91-98.	0.8	9
92	Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. International Journal of Cardiology, 2003, 90, 219-227.	0.8	32
93	Early Diagnosis of Primary Biliary Cirrhosis in Type 1 Diabetes: The possible role of eosinophilia. Diabetes Care, 2003, 26, 2963-2964.	4.3	4
94	Hypertension among HIV patients. Journal of Hypertension, 2003, 21, 1377-1382.	0.3	161
95	A New Emerging Risk Factor for Cardiovascular Disease: Apo(a) Polymorphism. Cardiology, 2003, 3, 159-163.	0.3	0
96	Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. Journal of Hypertension, 2003, 21, 1377-82.	0.3	116
97	Prevalence of Metabolic Syndrome Among HIV Patients. Diabetes Care, 2002, 25, 1253-1254.	4.3	81
98	Assessment of Asymptomatic Coronary Artery Disease in Apparently Uncomplicated Type 2 Diabetic Patients: A role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care, 2002, 25, 1418-1424.	4.3	48
99	High Prevalence of Metabolic Syndrome Among HIV–Infected Patients: Link With the Cardiovascular Risk. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 363-365.	0.9	41
100	Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism. Cardiovascular Diabetology, 2002, 1, 5.	2.7	32
101	Weight Loss after Swedish Adjustable Gastric Banding: Relationships to Insulin Resistance and Metabolic Syndrome. Obesity Surgery, 2002, 12, 841-845.	1.1	34
102	Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects. Diabetic Medicine, 2001, 18, 589-594.	1.2	29
103	Hypercalcémie sévère et lupus érythémateux disséminé. Revue Du Rhumatisme (Edition Francaise) 67, 646-650.	, 2000, 0.0	1
104	Severe hypercalcemia and systemic lupus erythematosus. Joint Bone Spine, 2000, 67, 485-8.	0.8	14
105	Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. Journal of the American College of Cardiology, 1999, 33, 157-163.	1.2	49
106	Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. Journal of the American College of Cardiology, 1999, 33, 157-63.	1.2	14
107	Genetics and cardiovascular risk: a role for apolipoprotein(a) polymorphism. Cardiologia: Bollettino Della Società Italiana Di Cardiologia, 1999, 44, 347-54.	0.0	2
108	Lipoprotein(a) levels and apolipoprotein(a) polymorphism in type 1 diabetes mellitus: relationships to microvascular and neurological complications. Acta Diabetologica, 1998, 35, 13-18.	1.2	16

#	Article	IF	CITATIONS
109	Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity. International Journal of Cardiology, 1998, 64, 277-284.	0.8	24
110	Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 37-42.	1.5	17
111	Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 37-42.	1.5	4
112	Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. Journal of Hypertension, 1997, 15, 227-235.	0.3	31
113	Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 191-197.	1.5	14
114	Serum lipoprotein(a) levels in adolescents and young adults with insulin-dependent diabetes mellitus. European Journal of Pediatrics, 1996, 155, 995-996.	1.3	1
115	Lipoprotein(a) Plasma Concentrations, Apolipoprotein (a) Polymorphism and Family History of Coronary Heart Disease in Patients with Essential Hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 191-197.	3.1	6
116	Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 191-7.	1.5	3
117	Lipoprotein(a), Apolipoprotein(a) Polymorphism, and Insulin Treatment in Type II Diabetic Patients. Diabetes Care, 1995, 18, 1202-1203.	4.3	8
118	Apo(a) isoforms: a genetic marker for progression of coronary atherosclerosis. Atherosclerosis, 1994, 109, 283.	0.4	4
119	Characterization of apo(a) polymorphism by a modified immunoblotting technique in an italian population sample. Clinica Chimica Acta, 1993, 221, 159-169.	0.5	43